Cancer Chemotherapy Update 
MECHANISM OF ACTION
Olaparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes (PARP-1, PARP-2, PARP-3). PARPs are enzymes needed for repair of single-strand DNA breaks. Inhibition of this pathway leads to accumulation of single-strand breaks, resulting in double-strand breaks in the DNA molecule.
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PHARMACOKINETICS
Following oral administration, absorption is rapid, with the peak concentration (C max ) between 1 and 3 hours. [50] [51] [52] The drug is approximately 82% protein bound. 52 The C max was reported to range from 4.7 mcg/mL to 9.1 mcg/mL; the time to maximum concentration (T max ) was 1 to 2 hours and 2 to 3 hours. [53] [54] [55] One study found a C max of 2,399.8 ± 1.371.5 mcg/L. 56 For oral doses ranging from 100 mg daily to 600 mg twice a day, the mean V d is 40.3 L. 50 Following a 400 mg oral dose, the V d is reported to be 167 ± 196 L. (CONT.)
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The AUC following 200 mg and 400 mg doses was 25.8 mcg•h/L and 58.1 mcg•h/L, respectively. 53 Following daily administration of 10 mg to 80 mg per day for 14 days, the AUC increased by approximately 26%. After twice-daily dosing with 60 mg to 600 mg per day for 14 days, the mean AUC increase was 49%. 50 Administration with a high-fat meal slows the T max , but does not significantly increase the AUC. 52, 56 Plasma clearance is 4.6 L/h; the elimination T ½ is 5 to 11 hours. 50, 51 Olaparnib is metabolized by oxidation followed by glucuronide or sulfate conjugation in the liver by CYP3A4. 52 Renal excretion accounts for about 44% of the drug, primarily as unchanged drug; about 15% is excreted as metabolites. 52 Forty-two percent of the drug is excreted in the feces, primarily as metabolites. 52 Selected therapeutic regimens of olaparib appear in ; constipation 17% to 21%, 51, 89 (grade 1) 9%, 88 (grade 2) 4%, 88 (grade 1 or 2) 7% to 16% 64, 82 ; diarrhea 25% to 27%, 51, 89 (grade 1) 2% to 23%, 77, 88 (grade 2) 4%, 88 (grade 1 or 2) 12% to 38%, 50, 61, 64, 82, 87 (grade 3 or 4) 2% to 3% [87] [88] [89] ; dysgeusia 25% to 33%, 51 
